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Intraoperative bleeding and the risk of post-operative bleeding constitute a particular challenge in the resection of spinal tumors, especially in children with a low total blood 
volume and may be life-threatening. Surgical treatment of spinal 
neurofibromas, which are benign tumors, can lead to difficulties 
in accomplishing hemostasis due to the high tumor vascularity 
and tissue friability [1].
Conventional treatment of coagulopathic bleeding consisting 
of fresh frozen plasma (FFP), packed red blood cell (RBC), and 
platelet transfusions can be insufficient. Recombinant activated 
factor VII (rFVIIa), initially used in hemophiliac patients with 
inhibitors or FVII-deficient patients, has been successfully used to 
correct bleeding in non-hemophilic children [2-3]. However, there 
are few reports about the use of rFVIIa in a child younger than 
1 year with refractory hemorrhage in neurosurgical interventions. 
We present a case of refractory bleeding during pediatric spinal 
neurofibromas surgery treated with rFVIIa.
CASE REPORT
A 5-month-old boy (weight 8 Kg) without a history of bleeding 
diathesis, presented to the neurosurgeon with a 1-month history 
of cries caused by any immobilization of the neck and the right 
upper limb.
On examination, the patient has a stilted attitude of the neck, 
axial hypotonia, and macrocranium. Many dermatologic “café au 
lait” spots were found in the back, in the chest, and in the limbs. 
Magnetic resonance imaging showed an intradural, extramedullary 
well-circumscribed mass ranging from C2 to C3 extending through 
the right neural foramina of C2 and C3 (Fig. 1). This mass was 
compressing the cervical medulla at its level. The diagnosis 
of Von Recklinghausen’s disease was retained. Pre-operative 
hematologic parameters were as follows: Hemoglobin 11.7 g/dL, 
prothrombin time (PT) 97%, activated cephalin time 33 s, platelet 
account 254 × 109/L, and fibrinogen 4.1 g/l.
In an operating room, anesthesia was induced with inhalation 
of 6% sevoflurane, followed by the insertion of two peripheral 
intravenous lines (left hand and left foot), then the child received 
sufentanil (2 µg) and cisatracurium (1 mg) intravenously and 
was intubated with orotracheal tube no. 4 without a cuff. The 
maintenance of anesthesia was performed with sevoflurane 
and sufentanil. Arterial line in the left radial artery for invasive 
measurement of blood pressure was inserted. The patient 
was operated for removal of the tumor through suboccipital 
craniectomy and C1C2 laminectomy.
Intraoperatively, an important bleeding originating from the 
occipital sinus was noticed. Hemostasis could only be obtained 
through clipping of the sinus. A complete excision of the tumor 
with decompression of the medulla was secured. Blood loss 
during this part of the procedure was 300 ml, 250 mL crystalloids 
and 100 mL colloids were infused. Laboratory testing revealed 
a hemoglobin of 6 g/dL, a platelet count of 78,000/L, a serum 
fibrinogen level of 1.2 g/l, a PT of 40 %, and an activated partial 
thromboplastin time (aPTT) of 45 s. A total of 400 ml of packed 
RBC, two units of platelets, 150 mL of FFP and 0.3 g of fibrinogen 
concentrate were administered.
The child was transferred to the intensive care unit (ICU) with 
the trachea intubated. 30 min after arrival in the ICU, he developed 
a voluminous tumefaction in front of the operative field and 
redon drain returned 350 cc of blood. The child was immediately 
brought back to the operative room. A bulky hematoma of the site 
of the tumor was evacuated, and Surgiflo® and Surgicel® were 
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placed in the operative site. Bleeding persisted after hematoma 
evacuation and resulted in hemorrhagic shock. Resuscitation 
required 650 ml of packed RBC, three units of platelets, 300 ml 
of FFP, 0.3 g of fibrinogen concentrate, 200 mg of tranexamic 
acid, and the infusion of dopamine (10 µg/kg per min). Since 
hemostatic treatments failed to control the bleeding, rFVIIa 
was administrated (90 g/kg in single intravenous injections). 
Hemodynamic status stabilized rapidly, blood loss decreased 
through the site of the tumor, and the hemorrhage was controlled 
within 30 min after rFVIIa administration.
The infant was transferred to the ICU with the trachea intubated, 
remained sedated and on ventilatory support. Laboratory testing on 
arrival to the ICU revealed the following: Hemoglobin 10.2 g/dL, 
platelet count of 84,000/L, serum fibrinogen level of 2.6 g/l, PT 
of 65 %, and an aPTT of 37 s. No additional need to transfuse 
blood products and dopamine infusion was rapidly stopped at 
the 2nd h post-operative. Wound drain output was 100 ml over 
the first 24 post-operative h. The child was weaned from the 
ventilator the next morning (20 h after rFVIIa administration), 
and the hemostasis parameters remained stable. Laboratory 
parameters obtained before and after rFVIIa are summarized in 
Table 1. There was no post-operative neurologic deficit. The child 
was discharged 1 week after the operation. 3 months later, the 
patient kept axial hypotonia partially improved by the functional 
re-education.
DISCUSSION
Massive bleeding in neurosurgical procedures worsens a patient’s 
prognosis, and for this reason, it is important to maintain 
functioning hemostasis. In this case, we report the benefit of 
rFVIIa to achieve hemostasis of refractory and life-threating 
intraoperative bleeding during pediatric spinal tumor surgery. The 
intravenous administration of rFVIIa (90 µg/kg) rapidly control 
hemorrhage and helps to stabilize hemodynamic status when 
conventional hemostatic treatments failed to stop bleeding. The 
rFVIIa was well tolerated and resulted in no adverse effects.
An acquired hemorrhagic disorder is related to multiple 
coagulation factor deficiencies and thrombocytopenia [4]. 
Recombinant FVIIa is a hemostatic agent used for the treatment 
of hemophilia A or B with inhibitors to coagulation factor VIII 
or IX. At present, it is designed to patients with congenital 
factor VII deficiency or the patients who have acquired antibodies 
to factor VIII [5,6]. Recombinant FVIIa stimulates the coagulation 
cascade by two mechanisms: Tissue factor (TF)-dependent and 
independent mechanisms. In the TF-dependent mechanism, 
FVIIa/TF complexes activate coagulation factors IX and X and 
activated factor X combines with factor V, leading to the thrombin 
generation. In the TF-independent mechanism, FVIIa can directly 
activate factor X on the platelet surface without the presence of 
TF. These mechanisms recruits, activate and aggregate platelets, 
resulting in the constitution of stabilized clots [7]. To ensure maximal 
rFVIIa efficacy, attempts should be made to achieve the following: 
Platelets >50,000 × 109/l; fibrinogen 0.5 to 1.0 g/l; pH ≥ 7.20; and 
hematocrit >24% [8].
The off-label use of rFVIIa for refractory bleeding has been 
increasing, and actually, it has been used for patients with bleeding 
associated with liver transplantation [9], cardiac surgery [10], 
trauma [11], and neurosurgical procedures [12]. There are few 
series concerning the use of rFVIIa in pediatric neurosurgery. 
Uhrig et al. [12] considered rFVIIa as a useful adjunct to control 
massive life-threatening bleeding during various pediatric 
neurosurgical procedures: Craniosynostosis surgery, emergency 
trauma surgery, and excision of a giant brain tumor. In these 
patients, the intravenous administration of rFVIIa (100 µg/kg) 
rapidly contributed to the reversal of hemorrhagic shock and 
allowed efficient surgical hemostasis when other classic means 
failed. In all but one patient, recovery was good, and no side 
effect related to the use of rFVIIa could be noted.
Heisel et al. [13] reported a series of pediatric neurosurgical 
patients (n=8) who received rFVIIa for the treatment of potentially 
life-threatening blood loss during brain tumor resection. In all 
but one of these procedures, there was an excellent response to 
rFVIIa, with control of bleeding and successful completion of the 
neurosurgical procedure. In these patients, rFVIIa was infused in 
a dose ranging from 75 to 225 µg/kg, and five children received a 
single injection. No side effects of rFVIIa were noted.
The recommended doses for surgical bleeding are between 
80 and 120 μg/kg [8]; however, the optimal doses for different 
indications are unknown. The maximal rate of thrombin 
generation is proportional to rFVIIa concentration, suggesting a 
Figure 1: Magnetic resonance imaging on T1 weighted sequence in 
coronal section showing a hyperintense well circumscribed mass 
ranging from C2 to C3 extending through the right neural foramina 
of C2 and C3
Table 1: Laboratory parameters before and after administration 
of rFVIIa
Laboratory 
parameters
Before 
surgery
Before 
rFVIIa
2 h after 
rFVIIa
12 h after 
rFVIIa
Hemoglobin (g/dL) 11.7 6 10.2 10.6
Platelet, 109/L 254 78 84 102
PT, % 97 40 65 88
ACT, sec 33 45 35 32
Fibrinogen, g/L 4.1 1.2 2.6 4.3
ACT: Activated cephalin time
Lotfi et al.  Recombinant activated factor VII in pediatric spinal tumor surgery
Vol 4 | Issue 6 | Nov - Dec 2018 Indian J Case Reports 446
dose-dependent effect [14,15]. The plasma clearance of rFVIIa 
is significantly higher in children than in adults; therefore, 
children might require a higher dose of rFVIIa than adults to 
achieve appropriate hemostasis [16]. In our case, rFVIIa dose is 
comparable with the recommended dose.
The most important problem is the risk that pharmacologic 
doses of rFVIIa may generate an acute thrombosis with or without 
hemophilia. The most reported cases of thromboembolic adverse 
events are on patients who received a higher dose of rFVIIa and 
suffering from sepsis [17].
CONCLUSION
We report the successful “off-label” use of recombinant factor 
VIIa in pediatric neurosurgery patient to control the intraoperative 
refractory bleeding when conventional hemostatic techniques 
were failed. No thromboembolic complications occurred after 
administration of rFVIIa in this case. Additional cases and studies 
are needed to define optimal dosing, drug efficacy, and drug 
safety in neurosurgery patients.
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